Contact: bertrand.collin@ube.fr
The IMATHERA (preclinical IMAging and radiation THERApy) platform, which is part of the nuclear medicine department of the Georges-François Leclerc Centre (CGFL) in Dijon, headed by Prof. Alexandre Cochet (IFTIM team), has 2 laboratories of around 550 m2 each, including one dedicated to preclinical imaging (CGFL site) and one dedicated to in vitro analyses (cytometry, cell testing microscopy, Erié site). The platform is accredited by the Autorité de Sûreté Nucléaire (ASN) and the Direction Départementale de la Protection des Populations (DDPP). Its highly specialised staff includes a multidisciplinary team led by Dr Bertrand Collin (RITM team).
For many years now, nuclear medicine has been a crucial tool both for the detection of cancers using molecular imaging and for the treatment of tumors using targeted radionuclide therapy.
The CGFL, a UNICANCER cancer centre, has technical expertise in preclinical and clinical imaging, as well as translational research capabilities through its Nuclear Medicine Department which hosts IMATHERA. In this context, IMATHERA aims to become a reference centre for the preclinical development of innovative theranostic strategies in oncology, pulmonary fibrosis, cardiovascular disease and preclinical imaging methodology.
Thanks to the radiochemistry, radiolabelling and quality control laboratories, it is possible to design innovative customised imaging probes using the latest generation equipment. Molecular probes are then evaluated in vitro and in vivo using a full range of equipment to adapt the detection technology to the biological problem: scintigraphy camera coupled to a scanner, PET (positron emission tomography) coupled to a scanner, PET coupled to MRI (magnetic resonance imaging), optical imaging or 2D imaging.
In each study carried out at IMATHERa, particular attention is paid to getting as close as possible to the clinical conditions encountered in patients by adapting the imaging probes developed as closely as possible to living conditions. To achieve this, models that are as close as possible to human pathology are used, using the same imaging modalities as in the clinical nuclear medicine department.
In-house Radiolabeling (Wide range of isotopes, dedicated shielded cabinets, expertise with various vector types
IN vitro studies (cytotoxicity studies, vector internalisation evaluation, Immunomodulation studies)
in vivo imaging studies (nuclear : PET/CT, SPECT/CT, PET/MRI; in vivo optical imaging)
In vivo TRT evaluation
Various animal models
Tumor growth evaluation
Toxicity studies
Imaging facilities
ICMUB members involved:
- Dr. Bertrand Collin (head of the plateform CGFL, RITM)
- Pr. Alexandre Cochet (head of the nuclear medicine department)
- Dr. Alan Courteau (CGFL, IFTIM)
- Dr. Mathieu Moreau (RITM)
- Dr. Sophie Poty (RITM)
The team also includes engineers and researchers from the CGFL, in particular Dr. Pierre-Simon Bellaye, Dr. Alexandre Dias, Dr. Alexandra Oudot and Dr. Alex Helbling.
Partners
IMATHERA is also a member of the UMS BIOSAND.
IMATHERA and ICMUB are fully involved in the Pharm’image® offering, from the design of molecules for radiotherapy (ICMUB, CheMatech) to patient image processing (CGFL, CHU Dijon) and preclinical validation (Oncodesign, IMATHERA), providing a unique range of expertises.
